The Journal of Pediatrics
Volume 149, Issue 5 , Pages 589-591 , November 2006

Recommendation for an adolescent dose of tetanus and diphtheria toxoids and acellular pertussis vaccine: Reassurance for the future

  • Scott A. Halperin, MD

      Affiliations

    • Halperin has received grant and contract funding from both manufacturers of adult formulation Tdap vaccines and has on occasion participated in consultancy meetings with both manufacturers on the subject of vaccines.
    • Corresponding Author InformationReprint requests: Scott A. Halperin, MD, Canadian Center for Vaccinology, Halifax, Dalhousie University, IWK Health Centre, 5850/5980 University Ave, Halifax, Nova Scotia B3K 6R8 Canada.

References 

  1. Guris D, Strebel PM, Bardenheier B, Brennan M, Tachdjian R, Finch E, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis. 1999;28:1230–1237
  2. Skowronski DM, De Serres G, MacDonald D, Wu W, Shaw C, Macnabb J, et al. The changing age and seasonal profile of pertussis in Canada [published correction appears in J Infect Dis 2002;185:1696]. J Infect Dis. 2002;185:1448–1453
  3. Centers for Disease Control and Prevention. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines (Recommendations of the Advisory Committee on Immunization Practices (ACIP)). MMWR Recomm Rep. 2006;55(RR-3):1–34
  4. Food and Drug Administration. Product approval information—licensing action, package insert: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed ADACEL™. Sanofi pasteur. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 2006. Available at http://www.fda.gov/cber/label/tdapave012306LB.pdf. Accessed June 28, 2006
  5. Food and Drug Administration. Product approval information—licensing action, package insert: BOOSTRIX®. Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed. GlaxoSmithKline Biologicals. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 2005. Available at http://www.fda.gov/cber/label/tdapgla122905LB.pdf. Accessed June 28, 2006
  6. Advisory Committee on Immunization Practices. ACIP votes to recommend use of combined tetanus diphtheria and pertussis (Tdap) vaccine for adults. Available at http://www.cdc.gov/nip/vaccine/tdap/tdap_adult_recs.pdf. Accessed June 28, 2006
  7. Public Health Agency of Canada. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI): Prevention of pertussis in adolescents and adults. Can Commun Dis Rep 2003;29(ACS-5):1-9.
  8. Halperin SA. Canadian experience with implementation of an acellular pertussis vaccine booster-dose program in adolescents: implications for the United States. Pediatr Infect Dis J. 2005;24:S141–S146
  9. Halperin SA, Scheifele D, Mills E, Guasparini R, Humphreys G, Barreto L, et al. Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine. Vaccine. 2003;21:2298–2306
  10. Halperin SA, Scheifele D, Barreto L, Pim C, Guasparini R, Medd L, et al. Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age. Pediatr Infect Dis J. 1999;18:772–779
  11. Skowronski DM, Remple VP, Macnabb J, Pielak K, Patrick DM, Halperin SA, et al. Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity, and anticipated impact. Pediatrics. 2003;112:e453–e459
  12. Scheifele DW, Halperin SA, Ferguson AC. Assessment of injection site reactions to an acellular pertussis-based combination vaccine, including novel use of skin tests with vaccine antigens. Vaccine. 2001;19:4720–4726
  13. Tam T, Scheifele DW. Local adverse reactions following a booster dose of acellular pertussis-DT vaccine: lack of effect of loratadine prophylaxis. 1996;Proceedings of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 15-18, (Abstract G104)
  14. Halperin SA, Smith B, Russell M, Hasselback P, Guasparini R, Skowronski D, et al. An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults. Vaccine. 2000;18:1312–1319
  15. Pichichero ME, Rennels MB, Edwards KM, Blatter MM, Marshall GS, Bologa M, et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA. 2005;293:3003–3011
  16. Pichichero ME, Blatter MM, Kennedy WA, Hedrick J, Descamps D, Friedland LR. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics. 2006;117:1084–1093
  17. Halperin S, Sweet L, Baxendale D. How soon after prior tetanus-diphtheria vaccination can one give an adult-formulation tetanus-diphtheria pertussis vaccine?. Pediatr Infect Dis J. 2006;25:195–200
  18. Halperin SA, Tapiero B, Law B, Diaz-Mitoma F, Duval B, Langley JM, et al. Interchangeability of two diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate vaccines as a fourth dose in 15-20-month-old toddlers. Vaccine. 2006;24:4017–4023
  19. Scheifele DW, Halperin SA, Ochnio JJ, Ferguson AC, Skowronski DM. A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial. Pediatr Infect Dis J. 2005;24:1059–1066Erratum in: Pediatr Infect Dis J 2006;25:229
  20. Zepp F, Knuf M, Habermehl P, Mannhardt-Laakmann W, Howe B, Friedland LR. Safety of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a 6th consecutive dose of acellular-pertussis containing vaccine. J Pediatr. 2006;149:603–610
  21. Rennels MB, Deloria MA, Pichichero ME, Losonsky GA, Englund JA, Meade BD, et al. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics. 2000;105:e12
  22. Woo EJ, Burwen DR, Gatumu SN, Ball R. Extensive limb swelling after immunization: reports to the Vaccine Adverse Event Reporting System. Clin Infect Dis. 2003;37:351–358
  23. Ward JI, Cherry JD, Chang SJ, Partridge S, Lee H, Treanor J, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med. 2005;353:1555–1563
  24. Disease Control and Epidemiology, Newfoundland and Labrador Department of Health and Community Services. Pertussis in Newfoundland and Labrador: 1991-2004. Can Commun Dis Rep. 2005;31:235–237
  25. Kandola K, Lea A, Santos M. Pertussis rates in Northwest Territories after introducing adult formulation acellular vaccine [abstract]. Can J Infect Dis Med Microbiol. 2004;15:351
  26. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Prevention and control of meningococcal disease. CDC MMWR Recomm Rep. 2005;54(RR-7):1–21

PII: S0022-3476(06)00795-5

doi: 10.1016/j.jpeds.2006.08.032

The Journal of Pediatrics
Volume 149, Issue 5 , Pages 589-591 , November 2006

Article Tools